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 The beginnings of nuclear medicine and 
radiology can be traced to the discovery of x-rays by 
Roentgen in 1895.   Roentgen’s announcement of the 
new phenomenon was closely followed by a flurry of 
related activity.   Many of the most illustrious 
scientists of the time immediately directed their 
energies toward a better understanding of radiation.  
For example, J.J. Thompson and Ernest Rutherford 
first reported their studies of the ionizing properties 
of radiation in 1896. 
 The medical applications of the new x-rays were 
obvious.  The first portable diagnostic machines were 
deployed for military purposes in 1898.  It was also 
quickly observed that the new rays, at sufficient level 
of intensity, could have dramatic effects on 
biological tissue and in particular that they could 
both cause, as well as eliminate, malignant growths.   
 In the same time frame, Becquerel made his 
historic discovery of natural radiation, Pierre and 
Marie Curie successfully identified and isolated 
radium and Rutherford, in collaboration with several 
others, made a series of discoveries including the 
fundamental demonstration that natural radiation is 
composed of three distinct components, alpha, beta, 
and gamma rays – still familiar to us today. 
 In the United States, Thomas Edison was one of 
the first to report on new findings concerning x-rays, 
and in fact he went on to invent the fluoroscope, and 
the company with which he was associated, General 
Electric, was an early leader in the manufacture and 
marketing of x-ray equipment.  Edison and, 
independently, Pierre Curie also suggested the use of 
internally-deposited radioactive materials for 
radiotherapy.  By 1905 many medical centers were 
implanting radium tubes in tumors and achieving 
demonstrable success. 
 As the new field of radiobiology developed in the 
1920’s and beyond, a number of improvements in the 
technology and procedures associated with medical 
radiological application were developed, continuing 
to this day with increasingly sophisticated external 
beam radiotherapy units and internal radionuclide 
applications with a diverse array of reactor- and 
accelerator-produced radionuclides and targeting 
protocols. 
 Application of neutrons for radiotherapy of 
cancer has also been a subject of clinical and research 
interest since the discovery of the neutron by 
Chadwick, in 1932.  For example, fast-neutron 
radiotherapy, which involves geometric targeting of a 
well-collimated high energy (15-20 MeV or greater) 
neutron beam onto the anatomical target region, 
much as is done with high-energy X-ray beams in 
photon radiotherapy, was first used by Robert Stone 
at Lawrence Berkeley Laboratory in 19381.  Fast-
neutron therapy is now an accepted modality for 
inoperable salivary gland tumors and it has shown 
promise for sarcomas, locally-advanced prostate 
cancer, and certain other malignancies as well2.
 Neutron capture therapy (NCT) is a somewhat 
different form of neutron-based therapy, first 
proposed as a general concept by Locher3.  In NCT, a 
neutron capture agent, which in current practice is 
10B (yielding Boron NCT, or BNCT), is selectively 
taken into the malignant tissue following the 
administration of a suitable boron delivery agent.  At 
an appropriate time after boron administration, the 
treatment volume is exposed to a field of thermal 
neutrons generated by the application of an external 
neutron beam produced by a small nuclear reactor or 
a suitable accelerator-based system.  The thermal 
neutrons interact with the 10B, which has a very high 
thermal-neutron capture cross section and which, 
ideally, is present only in the malignant cells.  Each 
boron-neutron interaction produces an alpha particle 
and a lithium ion.  These highly-energetic charged 
particles deposit their energy within a volume that is 
comparable to the size of the malignant cell, leading 
to a high probability of cell inactivation by direct 
DNA damage.  This process offers the possibility of 
highly selective destruction of malignant tissue, with 
cellular-level sparing of neighboring normal tissue.  
In a sense, BNCT can be viewed as a targeted 
radionuclide therapy with a mechanism for switching 
the emissions of the radionuclide on at a selected 
location in the body and nowhere else.   
 A third form of neutron therapy that combines the 
features of fast-neutron therapy and BNCT has also 
attracted research interest but has yet to be subjected 
to formal clinical trials.  In this modality4, a boron 
neutron capture agent is introduced preferentially 
into the malignant tissue prior to the administration 
of standard fast-neutron therapy.  Because a small 
fraction of the neutrons in fast-neutron therapy will 
be thermalized within the irradiation volume, it 
should be possible to selectively obtain a small 
incremental absorbed dose in the target volume from 
neutron capture.  In some cases this small 
incremental dose may be sufficient to produce a 
significant improvement in tumor control probability. 
 The first human trials of BNCT for brain tumors 
were conducted in the United States beginning in the 
early 1950s using reactor based thermal-neutron 
beams.  These trials were uniformly unsuccessful.  
Supporting technologies available at the time in the 
areas of chemistry, physics, and radiation dosimetry 
were insufficient for the task, the patients 
experienced no significant benefit, and there were 
unacceptable side effects.  Consequently, these early 
trials were discontinued.  However, researchers in 
Japan, led by Dr. Hiroshi Hatanaka, to whom this 
memorial lecture is dedicated, continued to explore 
the possibilities of NCT5.  In addition, the required 
technologies underwent continuous improvement.  
As a result, NCT experienced a resurgence of interest 
worldwide in the late 1980’s time frame.   
 In September 1994 BNCT trials resumed in the 
United States, at the Massachusetts Institute of 
Technology (MIT)6 and at Brookhaven National 
Laboratory (BNL) in New York7. These trials used 
epithermal-neutron beam extraction facilities 
backfitted to the MIT Research Reactor and the 
Brookhaven Medical Research Reactor, respectively. 
Boronated phenylalanine (BPA) was used as the 
boron delivery agent.  The Brookhaven trials were 
closed in 1999.  Clinical irradiations at MIT 
continued for a somewhat longer period of time, with 
the last few treatments conducted using a much-
improved epithermal beam based on a fission 
convertor concept8.  Trials of BNCT, primarily  for 
glioblastoma and melanoma, have also been initiated 
at various times over the past 15 years in Europe and 
South America and Clinical work currently is 
continuing in Japan, Finland, the Netherlands, the 
Czech Republic, Italy, and Argentina.
 Results of the various recent studies of 
epithermal-neutron BNCT have been encouraging, 
but do not constitute a significant breakthrough for 
BNCT as a clinical modality.  In general, 
observations to date indicate that treatment efficacy 
can be at least comparable to that of the best 
alternative standard treatments, but normal tissue 
complications are of concern in some situations and 
conclusive statistical proof of improved patient 
survival relative to standard treatments remains to be 
demonstrated.  
 A key feature of all of the BNCT clinical trials 
conducted to date has been the use of research 
reactor based neutron sources.  Until recently in 
Japan, as well as in the early American trials, thermal 
neutron beams were used.  In the United States and 
Europe the emphasis since 1987 has been on the use 
of higher-energy epithermal-neutron beams to 
produce the required thermal neutron flux at depth.   
Newer facilities in Japan also feature epithermal as 
well as hybrid thermal-epithermal neutron beams.  
Current technology for such beams has reached a 
high level of development.  For a given boron 
biodistribution, tumor to normal tissue dose ratios 
that are near the theoretical maximum that can be 
achieved by optimization of the incident neutron 
spectrum are routinely possible with this type of 
neutron source.    
 However, the supply of research reactors suitable 
for BNCT applications is limited and not all such 
reactors are conveniently located near the necessary 
medical infrastructure.  There are also perceived 
issues with licensing, safety, and operational 
procedures that might be associated with the use of 
research reactors in a hospital environment. Thus 
there has been considerable interest in the 
development of accelerator neutron sources suitable 
for BNCT applications. Coupled with advances in 
boron delivery agents and protocols that would 
reduce the neutron flux requirements compared to 
current practice, such neutron sources would 
generally be viewed as preferable for clinical 
implementation of BNCT as a routine modality.    
 Two types of accelerator neutron sources are of 
interest for BNCT research and clinical trials.  The 
first group of sources is composed of existing clinical 
fast-neutron facilities, which can be modified for 
exploration of NCT-augmented fast-neutron therapy 
at minimal additional cost.  Examples of such 
facilities where there has been an interest in 
applications of BNCT augmentation include the 
proton-cyclotron-based facility at the University of 
Washington, in Seattle, the proton linear accelerator 
facility at Fermi National Accelerator Laboratory, in 
Illinois, the deuteron cyclotron facilities at Harper 
Hospital in Detroit and in Essen, Germany as well as 
two accelerator facilities in France.  The second 
group of accelerator neutron sources for BNCT is 
composed of various developmental facilities 
designed to produce an epithermal neutron beam for 
BNCT as the primary therapy.   
The Clinical Neutron Therapy Center at the 
University of Washington (UW) offers an illustrative 
example of the use of an existing accelerator neutron 
facility for clinical studies of BNCT-augmented fast-
neutron therapy. In the UW facility protons are 
accelerated in a cyclotron to an energy of 50.5 MeV. 
 The resulting proton beam is directed by a series of 
magnets and focusing devices onto a 10.5 millimeter 
thick beryllium target located in the treatment head of 
an isocentric gantry system.  Neutrons produced in 
the target are subsequently directed through 
flattening and wedge filters and then through a 
multileaf collimator to produce the desired shaped 
neutron field at the isocenter.  Methods for 
optimizing the performance of the UW system for 
NCT-enhanced fast-neutron therapy applications 
have been explored9.  These efforts yielded a design 
for a new neutron production target capable of 
producing a neutron beam that yields essentially the 
same fast-neutron physical depth-dose curve as is the 
case with the current system, but which also has a 
significantly-increased low-energy spectral 
component.  In turn, this yields an increased fraction 
of BNCT enhancement relative to the total 
therapeutic dose, but with no difference in the 
physical fast-neutron dose delivered.  In-vivo clinical 
testing of BNCT-enhanced fast-neutron therapy for 
canine lung tumors has been conducted at UW and 
some limited human applications are described by 
Bucholtz4.
Early conceptual work10 at The Ohio State 
University and at MIT11,12 provided much of the 
initial basis for later development of epithermal-
neutron sources for BNCT using low-energy light-
ion accelerators.  Low-energy protons impinging on a 
lithium target have been the most popular method for 
driving accelerator-based systems designed to serve 
as neutron sources for epithermal-neutron BNCT, 
although other approaches, such as the deuteron-
beryllium interaction, and several others, have also 
been of interest. The threshold for the 7Li(p,n)7Be
interaction of interest is approximately 1.88 MeV. 
The neutrons produced, for example, by 2.5-MeV 
protons impinging on a lithium target have a 
maximum energy of approximately 800 keV in the 
forward direction.  Therefore less subsequent 
filtering and moderation of the neutron source 
emanating from the target is required to produce the 
desired epithermal source spectrum, relative to the 
case with the fission neutrons produced by a reactor, 
and in fact various studies have shown that the 
spectral quality of an optimized accelerator neutron 
source of this type can be nearly ideal, in some 
aspects better than the best reactor based neutron 
sources.   On the other hand, production of neutrons 
by a low-energy accelerator can be a rather 
inefficient process in terms of neutron production per 
incident charged particle on-target, creating a 
requirement for rather high particle currents and 
associated power deposition rates in the target.  There 
are thus many interrelated design factors to consider 
in connection with the optimization of such systems 
and there were many lively discussions in various 
venues during the early years regarding whether a 
practical and deployable accelerator neutron source 
could actually be developed for clinical-scale 
applications. 
By 1994 a number of additional research groups 
had begun to explore the possibilities of accelerator 
neutron sources for epithermal-neutron BNCT, and 
an international workshop sponsored by the US 
Department of Energy was held late in that year13.
Participants included researchers from the USA, 
Canada, the United Kingdom, Russia, Japan, 
Switzerland, Italy, Australia, Germany, Israel and 
India.  Topics covered included extensive discussions 
of various accelerator types and their advantages and 
disadvantages, computational studies of various 
systems, and various experimental studies focused on 
basic physics as well as practical engineering issues.  
The meeting produced a clear (and as it turned out 
very prescient) consensus that at least one, and 
probably more than one practical approach to the 
realization of a clinical-scale epithermal neutron 
source would in fact emerge from the various 
development efforts then underway. 
In the next few years following the 1994 
workshop several research groups did in fact 
successfully design, construct and demonstrate fully-
functional prototypes for accelerator neutron sources 
that were near-clinical in scale, or that demonstrated 
scalability to clinical levels.  An early demonstration 
of this type took place at the MIT Laboratory for 
Accelerator Beam Applications14.  This system was 
based on a 4 MeV tandem electrostatic accelerator 
that  produced either a proton or deuteron beam with 
a  maximum rated power level of 10 kW particle  
currents up to about 4 mA, depending on the desired 
particle energy.  With particle currents in this range, 
very significant neutron flux levels could be 
produced using lithium or beryllium as the 
accelerator target.  The charged particle beam passed 
through an adjustable bending magnet that directed 
the beam to any of several experiment stations.  Each 
of these stations could have its own target and 
neutron beam tailoring assembly.    Thus, the MIT 
facility could be used for innovative BNCT-related 
research in the areas of accelerator target design and 
moderator-filter design.  In addition, this facility 
provided sufficient neutron flux levels for 
meaningful BNCT radiobiological research.  One 
such initiative in this latter area involved the 
exploration of the possible application of BCNT 
techniques to the treatment of rheumatoid arthritis. 
In  the same general time frame, researchers at the 
University of Birmingham, in the United Kingdom, 
developed a slightly different variation for the design 
of a low-energy proton-beam-based accelerator 
epithermal neutron source for BNCT research15.  This 
design features a Dynamitron proton accelerator, a 
lithium target, and a neutron beam extraction 
arrangement that is at right angles to the axis of the 
proton beam impinging on a lithium target.  In the 
previous concepts, the axis of the incoming charged 
particle beam incident on the target was coincident 
with the outgoing neutron beam axis.  The use of the 
non-coaxial approach stems from certain practical 
considerations and provides some neutronic 
advantages.  The neutron spectrum emitted from the 
target in the direction perpendicular to the incident 
proton beam has a lower average energy than the 
forward-directed neutron spectrum, with relatively 
little penalty in total neutron yield.  In addition, 
neutrons emitted in the forward direction can also 
appear at the irradiation point, but only after losing 
some energy via at least one scattering interaction.  
The net result is that less filtering and moderating is 
required to produce an acceptable epithermal-neutron 
spectrum.  The vertical orientation of the proton 
beam also permits the target to be operated at liquid 
or near-liquid conditions, helping to solve a major 
engineering problem associated with lithium targets, 
which have a very low melting temperature 
In another clinical-scale system design effort 
during the late 1990s, researchers at the E.O. 
Lawrence Berkeley National Laboratory and the 
University of California at San Francisco developed a 
design and initiated the construction of a significantly 
higher power accelerator-based epithermal-neutron 
source16.   Unfortunately funding shortages prevented 
completion of this prototype, which featured an 
electrostatic quadrupole accelerator producing a 
proton beam that was directed onto a large-area 
water-cooled lithium target.  Several concepts for 
moderation and filtering of the resulting neutron 
source were explored and some low-power tests were 
conducted   A distinguishing feature of the neutron 
spectrum from one of the most promising of these 
concepts, based on neutron filtering in mixtures of 
lithium fluoride, aluminum fluoride, and aluminum, 
is that it is peaked near the high-energy end of the 
desirable epithermal-neutron range.  This yielded an 
improvement in the therapeutic ratio, compared to 
what was produced at the time by typical reactor-
based epithermal-neutron beams having a flat (per 
unit lethargy) spectrum over the epithermal energy 
range17.  The neutron flux intensity that was 
anticipated to be achievable with this device was 
comparable to the intensity of current reactor-based 
sources.
An additional interesting proton-accelerator-
based concept for an epithermal-neutron source 
useful for BNCT applications has been investigated 
by researchers in Russia18, as well as by Idaho State 
University and MIT19 and, more recently, in Japan20.
  This idea involves using an incident proton beam 
that has an energy that is just above the threshold for 
neutron production in the target.  In the case of a 
lithium target the threshold energy is 1.88 MeV and 
in the near-threshold concept the incident proton 
beam would have an energy of approximately 1.92 
MeV.  Under these conditions, the angular 
distribution of the neutrons emitted from the target is 
highly forward-peaked due to so-called “kinetic 
collimation”, an inherent feature of the kinematics of 
the neutron production interaction near the threshold, 
where the outgoing neutron has a velocity in the 
center of mass system that is smaller than the velocity 
of the center of mass.  In addition, the spectrum of 
the emitted neutrons is quite soft and may require 
little or no moderation and filtering to produce an 
acceptable therapeutic ratio in clinical applications.  
A difficulty with this concept is the fact that the 
neutron yield per unit proton current on target is 
smaller than with accelerator concepts that involve 
higher energy protons.  This is counteracted, 
however, by the reduced filtering requirements.  
There are other questions involving stability and 
target design for this concept, but if it can be realized 
in a practical and deployable device, it could offer a 
low-cost system for hospital deployment for some 
specialized applications. 
     Finally, during the mid-1990s the Idaho National 
Laboratory and Idaho State University,  investigated 
the feasibility of an alternate concept for an 
accelerator-based source of epithermal neutrons for 
BNCT that features a two-stage photoneutron 
production process driven by an electron accelerator. 
 In this concept relativistic electron beams impinge 
upon heavily-shielded tungsten targets located at the 
outer radius of a small cylindrical tank of circulating 
heavy water (D2O).   A fraction of the energy of the 
electrons is converted in the tungsten targets into 
radially-inward-directed bremsstrahlung radiation.   
Neutrons subsequently generated by 
photodisintegration of deuterons in the D2O within 
the tank are directed to the patient through a suitable 
beam tailoring system.   Initial proof-of-principal 
tests using a low-current benchtop prototype of the 
epithermal photoneutron source concept for BNCT 
were  conducted21.  The results of these experiments 
demonstrated that on the basis of neutronic 
performance, the proposed photoneutron device 
could offer a promising alternate approach to the 
production of epithermal neutrons for BNCT.  
However, control of photon contamination to 
acceptable levels at the irradiation point would be 
crucial to the success of the overall concept. 
    Further details and references relevant to the 
development of accelerator neutron sources for 
BNCT are available in the excellent recent review 
article by Blue and Yanch22.   Also, as is evident 
from the proceedings of the most recent three ISCNT 
meetings, including this one, solid progress in the 
field has continued, with the ongoing development 
and testing of the Birmingham facility, the 
construction of a clinical scale proton accelerator 
based neutron source by the Institute of Physics and 
Power Engineering in Obninsk, Russia, expanded 
efforts in Japan, and various other design studies and 
experimental tests in Russia, Italy, Korea, China, and 
Argentina. Perhaps most significantly at this 
particular juncture, a gantry-mounted neutron 
delivery system has been designed and is currently 
being constructed for a commercial customer by Ion 
Beam Applications Incorporated, in Belgium23.  This 
system will be the first gantry mounted neutron 
delivery system for epithermal-neutron BNCT.   It 
features a 20 mA proton beam incident on a high-
performance lithium target, with subsequent 
moderation and filtering of the resulting neutron 
source using a high-density MgF2 beam shaping 
assembly with a Pb reflector.  It arguably represents 
the current state of the art, based on the accumulated 
experience of researchers worldwide over the past 20 
years.
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